Answers are grounded in this paper and cite their sources.
Hypogonadism is one of the most consequential manifestations of prolactinoma in men, yet its course is often reduced to a single testosterone result. Prolactin excess can reversibly suppress hypothalamic-pituitary-gonadal signalling, whereas large tumours may damage gonadotroph function and other pituitary axes. These mechanisms create a dynamic phenotype that includes androgen-deficiency symptoms, impaired spermatogenesis, anaemia, adverse body composition, skeletal fragility and sexual dysfunction. Dopamine agonists are the usual first causal treatment, and transsphenoidal surgery is appropriate in selected patients; neither biochemical control nor tumour shrinkage proves gonadal or sexual recovery. Contemporary cohorts indicate that testosterone recovery occurs mainly during the first year but may continue through 24 months, and is more likely with smaller tumours, higher baseline or six-month testosterone, earlier prolactin normalisation and preserved pituitary function. Men with persistent symptomatic hypogonadism require a fertility-sensitive decision: continued observation when recovery remains plausible, consideration of testosterone replacement when fertility is not sought, or specialist gonadotrophin treatment when fertility is desired; clomiphene is an off-label option supported only by small uncontrolled studies. Sexual desire and erectile function should be measured separately because both may remain impaired despite eugonadism and require additional cardiometabolic, medication and psychosexual assessment. This Review integrates endocrine, reproductive and sexual outcomes into a time-resolved framework. The central principle is that prolactin control, endogenous gonadal recovery, fertility and sexual recovery are related but non-equivalent treatment goals.
No takes yet. Share an insight, caveat, or question.
Broul et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: